This request seems a bit unusual, so we need to confirm that you’re human. Please press and hold the button until it turns completely green. Thank you for your cooperation!
Press and hold the button
If you believe this is an error, please contact our support team.
192.64.82.12 : 9e005a60-8812-4155-a6d4-e73270c6
Just a moment… Enable JavaScript and cookies to continue This request seems a bit unusual, so we need to confirm that you’re human. Please press and hold the button until
Patients with monoclonal gammopathy of undetermined significance are at risk of progressing to multiple myeloma or a related cancer ─ even after 30 years of stability. These are the findings
The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center of the University of Pennsylvania shows
